Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × aflutinib × Clear all

Phase

Phase 2 30 Phase 1 5 Phase 1/2 4 Phase NA 3 Phase 3 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 77 Fluorouracil 52 Gemcitabine 51 Docetaxel 51 Paclitaxel 50 Oxaliplatin 48 Carboplatin 47 Capecitabine 47 Cyclophosphamide 46 Drug Therapy 42 Radiotherapy 40 pembrolizumab 33 Bevacizumab 30 Leucovorin 29 Doxorubicin 26 Dexamethasone 25 Magnetic Resonance Spectroscopy 23 Cytarabine 23 Etoposide 22 Nivolumab 21 Pemetrexed 20 Methotrexate 20 Radiation 16 apatinib 15 Prednisone 15 venetoclax 14 Vincristine 14 Temozolomide 14 Folfox protocol 14 Epirubicin 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡